Revitope Oncology is driving immune-control of solid tumors.
Immune-based therapies are redefining how cancer is treated, as clinical studies demonstrate unprecedented deep and durable responses in multiple cancer types. In particular, redirecting T cells to tumors is a successful strategy for immunotherapy, but to date is limited by off-target toxicities and imperfect targets for solid tumors.
Revitope’s engineered antibody circuits are focusing immune activation to the cancer cell surface while expanding the antigenic targeting space on solid tumors to widen the therapeutic index in immune-oncology.
- Mark Cobbold, MD, PhD Co-Founder
- Andrew Allen, MD, PhD Co-Founder and Chairman
- Werner Meier Chief Scientific Officer, acting CEO